

Anthony E Lang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11819126/publications.pdf>

Version: 2024-02-01

542
papers

76,057
citations

764

119
h-index

640

256
g-index

573
all docs

573
docs citations

573
times ranked

42686
citing authors

#	ARTICLE	IF	CITATIONS
1	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	2.2	4,796
2	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	2.2	4,389
3	Parkinson's disease. <i>Lancet, The</i> , 2015, 386, 896-912.	6.3	4,079
4	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17013.	18.1	3,048
5	Parkinson's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1044-1053.	13.9	1,876
6	Phenomenology and classification of dystonia: A consensus update. <i>Movement Disorders</i> , 2013, 28, 863-873.	2.2	1,754
7	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. <i>New England Journal of Medicine</i> , 2000, 342, 1484-1491.	13.9	1,467
8	Criteria for the diagnosis of corticobasal degeneration. <i>Neurology</i> , 2013, 80, 496-503.	1.5	1,445
9	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	2.2	1,402
10	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology, The</i> , 2008, 7, 583-590.	4.9	1,340
11	Impulse Control Disorders in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 589-95.	4.9	1,244
12	Parkinson's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1130-1143.	13.9	1,147
13	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	2.2	1,097
14	Pharmacological Treatment of Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1670.	3.8	1,097
15	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	2.2	1,033
16	Randomized controlled trial of intraputaminal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , 2006, 59, 459-466.	2.8	890
17	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003, 54, 93-101.	2.8	820
18	Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. <i>Movement Disorders</i> , 2006, 21, S290-S304.	2.2	811

#	ARTICLE	IF	CITATIONS
19	Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. <i>Brain</i> , 2002, 125, 1196-1209.	3.7	645
20	Beta Oscillatory Activity in the Subthalamic Nucleus and Its Relation to Dopaminergic Response in Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2006, 96, 3248-3256.	0.9	520
21	Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 455.	3.8	509
22	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. <i>Annals of Neurology</i> , 2003, 54, S15-S19.	2.8	496
23	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016, 31, 1272-1282.	2.2	464
24	A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. <i>Brain</i> , 2008, 131, 2720-2728.	3.7	460
25	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. <i>JAMA Neurology</i> , 2018, 75, 1132.	4.5	455
26	Posteroventral Medial Pallidotomy in Advanced Parkinson's Disease. <i>New England Journal of Medicine</i> , 1997, 337, 1036-1043.	13.9	453
27	Ten-Year Outcome of Subthalamic Stimulation in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 1550.	4.9	397
28	Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 578-586.	2.2	382
29	Globus pallidus internus pallidotomy for generalized dystonia. <i>Movement Disorders</i> , 1997, 12, 865-870.	2.2	379
30	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	2.2	379
31	Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2006, 66, 845-851.	1.5	371
32	Impulse control disorders in parkinson disease: A multicenter case-control study. <i>Annals of Neurology</i> , 2011, 69, 986-996.	2.8	361
33	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. <i>Annals of Neurology</i> , 2010, 68, 18-27.	2.8	330
34	Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 1460.	4.9	326
35	Factors Associated With Dopaminergic Drug-Related Pathological Gambling in Parkinson Disease. <i>Archives of Neurology</i> , 2007, 64, 212.	4.9	322
36	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002, 50, 1268-1276.	0.6	314

#	ARTICLE	IF	CITATIONS
37	Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. <i>Journal of Neurosurgery</i> , 2003, 99, 489-495.	0.9	306
38	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2009, 22, 430-436.	1.8	303
39	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology</i> , The, 2017, 16, 552-563.	4.9	303
40	Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. <i>Lancet Neurology</i> , The, 2004, 3, 309-316.	4.9	302
41	Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 716.	4.9	295
42	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. <i>Lancet Neurology</i> , The, 2007, 6, 652-662.	4.9	290
43	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , 2006, 129, 1059-1069.	3.7	286
44	Mutations in GNAL cause primary torsion dystonia. <i>Nature Genetics</i> , 2013, 45, 88-92.	9.4	281
45	Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , 2016, 12, 65-66.	4.9	279
46	Primary Dystonia Is More Responsive than Secondary Dystonia to Pallidal Interventions: Outcome after Pallidotomy or Pallidal Deep Brain Stimulation. <i>Neurosurgery</i> , 2004, 54, 613-621.	0.6	278
47	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , 2018, 33, 660-677.	2.2	275
48	Clinical Correlations With Lewy Body Pathology in <i>LRRK2</i> -Related Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 100.	4.5	272
49	Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. <i>Journal of Neurosurgery</i> , 2002, 97, 1152-1166.	0.9	267
50	A comparison of the mini mental state exam to the montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 297-299.	2.2	266
51	Long-Term Follow-up of Unilateral Pallidotomy in Advanced Parkinson's Disease. <i>New England Journal of Medicine</i> , 2000, 342, 1708-1714.	13.9	263
52	Deep brain stimulation: Preoperative issues. <i>Movement Disorders</i> , 2006, 21, S171-S196.	2.2	260
53	Short and long latency afferent inhibition in Parkinson's disease. <i>Brain</i> , 2003, 126, 1883-1894.	3.7	258
54	Neuropsychological Outcome of GPi Pallidotomy and GPi or STN Deep Brain Stimulation in Parkinson's Disease. <i>Brain and Cognition</i> , 2000, 42, 324-347.	0.8	255

#	ARTICLE	IF	CITATIONS
55	α-Synuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013, 73, 155-169.	2.8	255
56	Caffeine for treatment of Parkinson disease. <i>Neurology</i> , 2012, 79, 651-658.	1.5	252
57	Pallidal neuronal activity: Implications for models of dystonia. <i>Annals of Neurology</i> , 2003, 53, 480-488.	2.8	246
58	Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. <i>Movement Disorders</i> , 2006, 21, 1941-1946.	2.2	245
59	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685.	4.9	245
60	Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. <i>Movement Disorders</i> , 2004, 19, 656-662.	2.2	240
61	Interface between tauopathies and synucleinopathies: A tale of two proteins. <i>Annals of Neurology</i> , 2006, 59, 449-458.	2.8	240
62	Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. <i>Nature Genetics</i> , 2015, 47, 579-581.	9.4	237
63	Apraxia in movement disorders. <i>Brain</i> , 2005, 128, 1480-1497.	3.7	228
64	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002, 50, 1268-1276.	0.6	227
65	Stimulation of the subthalamic nucleus and impulsivity: Release your horses. <i>Annals of Neurology</i> , 2009, 66, 817-824.	2.8	225
66	Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018, 84, 797-811.	2.8	225
67	Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2019, 380, 315-324.	13.9	225
68	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 248-257.	2.8	224
69	Practical guidelines for managing adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , 2015, 17, 599-609.	1.1	222
70	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007, 22, 2409-2417.	2.2	221
71	Distribution, type, and origin of Parkin mutations: Review and case studies. <i>Movement Disorders</i> , 2004, 19, 1146-1157.	2.2	219
72	Hemiballism: revisiting a classic disorder. <i>Lancet Neurology</i> , The, 2003, 2, 661-668.	4.9	217

#	ARTICLE	IF	CITATIONS
73	Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. <i>Nature Medicine</i> , 1997, 3, 671-674.	15.2	216
74	Bilateral globus pallidus stimulation for Huntington's disease. <i>Annals of Neurology</i> , 2004, 56, 290-294.	2.8	207
75	The prion hypothesis in Parkinson's disease: Braak to the future. <i>Acta Neuropathologica Communications</i> , 2013, 1, 2.	2.4	205
76	Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. <i>Neurology</i> , 2003, 61, 1601-1604.	1.5	204
77	Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results. <i>Movement Disorders</i> , 2015, 30, 500-509.	2.2	199
78	Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , 2006, 59, 825-834.	2.8	195
79	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.	1.5	194
80	Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: A functional MRI case study. <i>Movement Disorders</i> , 2003, 18, 1508-1516.	2.2	191
81	Parkinsonian syndromes associated with hydrocephalus: Case reports, a review of the literature, and pathophysiological hypotheses. <i>Movement Disorders</i> , 1994, 9, 508-520.	2.2	188
82	Disease-modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1442-1450.	2.2	188
83	Chorein detection for the diagnosis of chorea-acanthocytosis. <i>Annals of Neurology</i> , 2004, 56, 299-302.	2.8	186
84	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. <i>Movement Disorders</i> , 2002, 17, 303-312.	2.2	183
85	Predicting Motor Decline and Disability in Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 1724.	4.9	179
86	Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. <i>Neurology</i> , 2013, 80, 1698-1701.	1.5	178
87	Teaching tape for the motor section of the toronto western spasmodic torticollis scale. <i>Movement Disorders</i> , 1997, 12, 570-575.	2.2	177
88	Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , 2017, 6, 8.	3.6	177
89	Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated With Older (Ergot) vs Newer (Nonergot) Dopamine Agonists. <i>Archives of Neurology</i> , 2004, 61, 97.	4.9	174
90	Overview of the Extranigral Aspects of Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 167-72.	4.9	172

#	ARTICLE	IF	CITATIONS
91	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	2.2	171
92	Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms. <i>Brain</i> , 2001, 124, 2105-2118.	3.7	168
93	Multiple system atrophy—parkinsonism with slow progression and prolonged survival: A diagnostic catch. <i>Movement Disorders</i> , 2012, 27, 1186-1190.	2.2	164
94	Crossroads in GDNF therapy for Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 136-141.	2.2	163
95	The Fragile X Premutation Presenting as Essential Tremor. <i>Archives of Neurology</i> , 2003, 60, 117.	4.9	162
96	Analysis of the PINK1 Gene in a Large Cohort of Cases With Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1898-904.	4.9	162
97	Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. <i>Brain</i> , 1999, 122, 405-416.	3.7	153
98	Deep brain stimulation for Parkinson's disease: Patient selection and evaluation. <i>Movement Disorders</i> , 2002, 17, S94-S101.	2.2	150
99	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. <i>Neurology</i> , 2014, 82, 1791-1797.	1.5	147
100	Development of dyskinesias in a 5-year trial of ropinirole and L -dopa. <i>Movement Disorders</i> , 2006, 21, 1844-1850.	2.2	145
101	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017, 32, 319-324.	2.2	145
102	Gut-brain axis and the spread of α -synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019, 34, 307-316.	2.2	144
103	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 119-126.	4.9	141
104	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009, 34, 2758-2766.	2.8	140
105	Premotor Parkinson's disease: Concepts and definitions. <i>Movement Disorders</i> , 2012, 27, 608-616.	2.2	140
106	Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. <i>Brain</i> , 2014, 137, 2143-2154.	3.7	140
107	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. <i>Movement Disorders</i> , 2009, 24, 1366-1374.	2.2	138
108	Psychogenic Dystonia: a Review of 18 Cases. <i>Canadian Journal of Neurological Sciences</i> , 1995, 22, 136-143.	0.3	137

#	ARTICLE	IF	CITATIONS
109	Progressive ataxia and palatal tremor (PAPT): Clinical and MRI assessment with review of palatal tremors. <i>Brain</i> , 2004, 127, 1252-1268.	3.7	134
110	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , 2017, 82, 503-513.	2.8	133
111	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010, 68, 963-968.	2.8	132
112	Association Between Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome. <i>JAMA Neurology</i> , 2013, 70, 1359.	4.5	132
113	Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. <i>Neurogenetics</i> , 2013, 14, 11-22.	0.7	131
114	Prediction of cognition in Parkinson's disease with a clinical genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , The, 2017, 16, 620-629.	4.9	131
115	The nonmotor symptoms of Parkinson's disease—An overview. <i>Movement Disorders</i> , 2010, 25, S123-30.	2.2	130
116	Colonic mucosal α -synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , 2015, 84, 609-616.	1.5	130
117	Neuronal Firing Rates and Patterns in the Globus Pallidus Internus of Patients With Cervical Dystonia Differ From Those With Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2007, 98, 720-729.	0.9	129
118	A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials. <i>Movement Disorders</i> , 2011, 26, 775-783.	2.2	128
119	Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the <i>TUBB4</i> gene. <i>Annals of Neurology</i> , 2013, 73, 537-545.	2.8	128
120	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , The, 2013, 12, 514-524.	4.9	126
121	Gait abnormalities in psychogenic movement disorders. <i>Movement Disorders</i> , 2007, 22, 395-399.	2.2	125
122	Punding prevalence in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1179-1181.	2.2	125
123	The Nature and Time Course of Cortical Activation Following Subthalamic Stimulation in Parkinson's Disease. <i>Cerebral Cortex</i> , 2010, 20, 1926-1936.	1.6	125
124	From psychogenic movement disorder to functional movement disorder: It's time to change the name. <i>Movement Disorders</i> , 2014, 29, 849-852.	2.2	125
125	Antidepressant Treatment Outcomes of Psychogenic Movement Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1529-1534.	1.1	125
126	Extra-striatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study. <i>Neurobiology of Disease</i> , 2012, 48, 519-525.	2.1	123

#	ARTICLE	IF	CITATIONS
127	Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease With Modafinil. <i>Clinical Neuropharmacology</i> , 2002, 25, 111-114.	0.2	122
128	Predictors of deterioration in health-related quality of life in Parkinson's disease: Results from the DATATOP trial. <i>Movement Disorders</i> , 2008, 23, 653-659.	2.2	122
129	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013, 28, 1838-1846.	2.2	122
130	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	2.2	121
131	Î±-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , 2016, 39, 750-762.	4.2	120
132	Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease. <i>Neurotherapeutics</i> , 2014, 11, 6-23.	2.1	119
133	Involvement of the cerebellothalamocortical pathway in Parkinson disease. <i>Annals of Neurology</i> , 2010, 68, 816-824.	2.8	117
134	Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. <i>Brain</i> , 2014, 137, 565-575.	3.7	116
135	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology</i> , The, 2019, 18, 865-879.	4.9	116
136	Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1392-1397.	2.2	115
137	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	2.2	114
138	Placebo effect of medication cost in Parkinson disease. <i>Neurology</i> , 2015, 84, 794-802.	1.5	112
139	Involvement of human thalamus in the preparation of self-paced movement. <i>Brain</i> , 2004, 127, 2717-2731.	3.7	111
140	The progression of Parkinson disease. <i>Neurology</i> , 2007, 68, 948-952.	1.5	109
141	Phenotype-Specific Diagnosis of Functional (Psychogenic) Movement Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 32.	2.0	108
142	Analysis of the glucocerebrosidase gene in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 367-370.	2.2	107
143	<i>Helicobacter pylori</i> infection is associated with worse severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 221-225.	1.1	107
144	Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 990-997.	2.2	106

#	ARTICLE	IF	CITATIONS
145	Non-dopaminergic treatments in development for Parkinson's disease. <i>Lancet Neurology, The</i> , 2008, 7, 927-938.	4.9	106
146	Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. <i>Annals of Neurology</i> , 2009, 66, 110-114.	2.8	106
147	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 1077-1081.	2.2	106
148	The treatment of dystonic tremor: a systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 759-769.	0.9	105
149	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 251-257.	0.9	104
150	Impairments of speed and amplitude of movement in Parkinson's disease: A pilot study. <i>Movement Disorders</i> , 2009, 24, 1001-1008.	2.2	104
151	Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. <i>Lancet Neurology, The</i> , 2020, 19, 452-461.	4.9	104
152	Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: Support for the existence of cognitive circuits in the human pallidum. <i>Brain</i> , 2000, 123, 746-758.	3.7	103
153	Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 130-135.	0.9	103
154	Disease modification and biomarker development in Parkinson disease. <i>Neurology</i> , 2020, 94, 481-494.	1.5	103
155	Caffeine as symptomatic treatment for Parkinson disease (Caf@PD). <i>Neurology</i> , 2017, 89, 1795-1803.	1.5	102
156	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309942.	0.9	100
157	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology, The</i> , 2016, 15, 954-966.	4.9	100
158	Probiotics for Constipation in Parkinson Disease. <i>Neurology</i> , 2021, 96, e772-e782.	1.5	100
159	Historical and Clinical Features of Psychogenic Tremor: a Review of 70 Cases. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, 190-195.	0.3	99
160	Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure. <i>Movement Disorders</i> , 2006, 21, 1578-1594.	2.2	99
161	Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: A [¹⁵ O] H ₂ O PET study. <i>Human Brain Mapping</i> , 2009, 30, 3901-3909.	1.9	99
162	Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-omics. <i>Annals of Neurology</i> , 2021, 89, 546-559.	2.8	99

#	ARTICLE	IF	CITATIONS
163	Psychogenic Movement Disorders. Canadian Journal of Neurological Sciences, 2003, 30, S94-S100.	0.3	97
164	The cerebellothalamocortical pathway in essential tremor. Neurology, 2003, 60, 1985-1987.	1.5	97
165	Interhemispheric and ipsilateral connections in Parkinson's disease: Relation to mirror movements. Movement Disorders, 2007, 22, 813-821.	2.2	97
166	Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Annals of Neurology, 2004, 55, 761-765.	2.8	95
167	Manganese-Induced Parkinsonism Associated With Methcathinone (Ephedrone) Abuse. Archives of Neurology, 2007, 64, 886.	4.9	95
168	Characterization of REM-Sleep Associated Ponto-Geniculo-Occipital Waves in the Human Pons. Sleep, 2007, 30, 823-827.	0.6	95
169	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. PLoS ONE, 2015, 10, e0138721.	1.1	95
170	Parietal Pick's disease mimicking cortical basal ganglionic degeneration. Neurology, 1994, 44, 1436-1436.	1.5	95
171	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. Journal of Medical Genetics, 2012, 49, 721-726.	1.5	94
172	The microbiome "gut-brain axis in Parkinson disease" from basic research to the clinic. Nature Reviews Neurology, 2022, 18, 476-495.	4.9	94
173	Levodopa-related motor complications-Phenomenology. Movement Disorders, 2008, 23, S509-S514.	2.2	93
174	Psychogenic facial movement disorders: Clinical features and associated conditions. Movement Disorders, 2012, 27, 1544-1551.	2.2	93
175	Stereotypies: A critical appraisal and suggestion of a clinically useful definition. Movement Disorders, 2012, 27, 179-185.	2.2	93
176	Saliency network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. Annals of Neurology, 2015, 77, 269-280.	2.8	93
177	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	2.2	93
178	Extrastriatal dopaminergic dysfunction in tourette syndrome. Annals of Neurology, 2010, 67, 170-181.	2.8	92
179	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. Movement Disorders, 2015, 30, 150-159.	2.2	92
180	The many faces of corticobasal degeneration. Parkinsonism and Related Disorders, 2007, 13, S336-S340.	1.1	91

#	ARTICLE	IF	CITATIONS
181	Integrated safety of levodopa+carbidopa intestinal gel from prospective clinical trials. <i>Movement Disorders</i> , 2016, 31, 538-546.	2.2	91
182	Benign hereditary chorea: Clinical, genetic, and pathological findings. <i>Annals of Neurology</i> , 2003, 54, 244-247.	2.8	90
183	Corticobasal Ganglionic Degeneration and Progressive Supranuclear Palsy Presenting with Cognitive Decline. <i>Brain Pathology</i> , 1998, 8, 355-365.	2.1	89
184	Investigation of C9orf72 in 4 Neurodegenerative Disorders. <i>Archives of Neurology</i> , 2012, 69, 1583.	4.9	89
185	Tics and functional tic-like movements. <i>Neurology</i> , 2019, 93, 750-758.	1.5	89
186	Impairment of motor cortex activation and deactivation in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2001, 112, 600-607.	0.7	88
187	Vascular Parkinsonism: Deconstructing a Syndrome. <i>Movement Disorders</i> , 2015, 30, 886-894.	2.2	88
188	Mutation analysis of CHCHD10 in different neurodegenerative diseases. <i>Brain</i> , 2015, 138, e380-e380.	3.7	86
189	Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: A case report. <i>Movement Disorders</i> , 2004, 19, 969-972.	2.2	84
190	Chronic acquired hepatocerebral degeneration: Case reports and new insights. <i>Movement Disorders</i> , 1995, 10, 714-722.	2.2	83
191	Surgery for Parkinson Disease. <i>Archives of Neurology</i> , 2000, 57, 1118.	4.9	83
192	Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. <i>Nature Medicine</i> , 2010, 16, 1223-1226.	15.2	83
193	Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. <i>Brain</i> , 2011, 134, 2096-2105.	3.7	83
194	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009, 34, 2758-66.	2.8	83
195	New developments in understanding the etiology of Parkinson's disease and in its treatment. <i>Current Opinion in Neurobiology</i> , 1998, 8, 783-790.	2.0	82
196	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 546-548.	4.9	82
197	Posttraumatic painful torticollis. <i>Movement Disorders</i> , 2003, 18, 1482-1491.	2.2	81
198	Dopaminergic transplantation for parkinson's disease: Current status and future prospects. <i>Annals of Neurology</i> , 2009, 66, 591-596.	2.8	80

#	ARTICLE	IF	CITATIONS
199	Movement Disorders on YouTube â€” Caveat Spectator. <i>New England Journal of Medicine</i> , 2011, 365, 1160-1161.	13.9	77
200	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 638-649.	0.9	77
201	Stimulation of the Subthalamic Nucleus in Parkinson's Disease Does Not Produce Striatal Dopamine Release. <i>Neurosurgery</i> , 2003, 53, 1095-1105.	0.6	76
202	Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 566-571.	0.9	76
203	â€œUnder pressureâ€™: is there a link between orthostatic hypotension and cognitive impairment in Î±-synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1311-1321.	0.9	75
204	Pallidal Stimulation in Parkinson's Disease Patients with a Prior Unilateral Pallidotomy. <i>Canadian Journal of Neurological Sciences</i> , 1998, 25, 300-305.	0.3	74
205	Alimentary, my dear Watson? The challenges of enteric Î±-synuclein as a Parkinson's disease biomarker. <i>Movement Disorders</i> , 2014, 29, 444-450.	2.2	74
206	Essential pitfalls in â€œessentialâ€™ tremor. <i>Movement Disorders</i> , 2017, 32, 325-331.	2.2	74
207	Peroxisomal D-bifunctional protein deficiency. <i>Neurology</i> , 2014, 82, 963-968.	1.5	73
208	Clinical and neural responses to cognitive behavioral therapy for functional tremor. <i>Neurology</i> , 2019, 93, e1787-e1798.	1.5	73
209	Firing rates of pallidal neurons are similar in Huntingtonâ€™s and Parkinsonâ€™s disease patients. <i>Experimental Brain Research</i> , 2005, 166, 230-236.	0.7	72
210	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 196-202.	0.3	72
211	Criteria for deep-brain stimulation in Parkinsonâ€™s disease: review and analysis. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1695-1705.	1.4	71
212	Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 58-64.	1.1	71
213	Dystonia and Parkinson's disease: What is the relationship?. <i>Neurobiology of Disease</i> , 2019, 132, 104462.	2.1	71
214	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019, 8, 28.	3.6	70
215	Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. <i>Current Opinion in Neurology</i> , 2018, 31, 484-490.	1.8	69
216	Subthalamic nucleusâ€™ deep brain stimulation for early motor complications in Parkinson's diseaseâ€™ the EARLYSTIM trial: Early is not always better. <i>Movement Disorders</i> , 2014, 29, 1751-1756.	2.2	68

#	ARTICLE	IF	CITATIONS
217	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , 2016, 31, 290-298.	2.2	68
218	Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?. <i>Annals of Neurology</i> , 2013, 73, 565-575.	2.8	67
219	Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , 2018, 17, 179-187.	1.4	67
220	Hemiballism in multiple sclerosis. <i>Movement Disorders</i> , 1988, 3, 88-94.	2.2	66
221	Involvement of the Basal Ganglia and Cerebellar Motor Pathways in the Preparation of Self-Initiated and Externally Triggered Movements in Humans. <i>Journal of Neuroscience</i> , 2007, 27, 6029-6036.	1.7	65
222	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020, 11, 572976.	1.1	65
223	Dopamineâ€agonists and impulsivity in Parkinson's disease: Impulsive choices vs. impulsive actions. <i>Human Brain Mapping</i> , 2014, 35, 2499-2506.	1.9	64
224	Cortical Plasticity Induction by Pairing Subthalamic Nucleus Deep-Brain Stimulation and Primary Motor Cortical Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2016, 36, 396-404.	1.7	64
225	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimerâ€™s Disease and Parkinsonâ€™s Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 120.	1.7	64
226	Alterations of striatal neurons in benign hereditary chorea. <i>Movement Disorders</i> , 2005, 20, 1353-1357.	2.2	63
227	Behavioral effects of levodopa. <i>Movement Disorders</i> , 2015, 30, 90-102.	2.2	63
228	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 102-106.	1.1	63
229	GDNF and Parkinsonâ€™s Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , 2020, 10, 875-891.	1.5	63
230	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021, 27, 1451-1457.	15.2	63
231	Deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, S168-S170.	2.2	62
232	Hereditary parkinsonism: Parkinson disease lookâ€alikesâ€ An algorithm for clinicians to âœPARK</i> genes and beyond. <i>Movement Disorders</i> , 2009, 24, 2042-2058.	2.2	62
233	<i>ATP13A2</i> variants in earlyâ€onset Parkinson's disease patients and controls. <i>Movement Disorders</i> , 2009, 24, 2104-2111.	2.2	62
234	Striatonigral Degeneration: Iron Deposition in Putamen Correlates with the Slit-like Void Signal of Magnetic Resonance Imaging. <i>Canadian Journal of Neurological Sciences</i> , 1994, 21, 311-318.	0.3	61

#	ARTICLE	IF	CITATIONS
235	Response to clozapine in a clinically identifiable subtype of schizophrenia. <i>British Journal of Psychiatry</i> , 2015, 206, 484-491.	1.7	61
236	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinson's Disease</i> , 2016, 2, .	2.5	61
237	Common Myths in the Use of Levodopa in Parkinson Disease. <i>JAMA Neurology</i> , 2017, 74, 633.	4.5	60
238	Sustained relief of dystonia following cessation of deep brain stimulation. <i>Movement Disorders</i> , 2007, 22, 1958-1962.	2.2	59
239	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 86-95.	2.2	59
240	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-ON PD III). <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 360-368.	1.7	59
241	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. <i>Neurology</i> , 2021, 97, 942-957.	1.5	58
242	Motor neuron disease-inclusion dementia presenting as cortical-basal ganglionic degeneration. <i>Movement Disorders</i> , 1999, 14, 674-680.	2.2	57
243	Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020, 35, 1755-1764.	2.2	57
244	rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: A PET study. <i>Movement Disorders</i> , 2008, 23, 1051-1054.	2.2	56
245	Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. <i>Neurology</i> , 2014, 82, 2250-2251.	1.5	56
246	Global investigation and meta-analysis of the G4C2 repeat in Parkinson disease. <i>Neurology</i> , 2014, 83, 1906-1913.	1.5	56
247	Single Pulse Stimulation of the Human Subthalamic Nucleus Facilitates the Motor Cortex at Short Intervals. <i>Journal of Neurophysiology</i> , 2004, 92, 1937-1943.	0.9	55
248	Characteristic head drops and axial extension in advanced chorea-acanthocytosis. <i>Movement Disorders</i> , 2010, 25, 1487-1491.	2.2	54
249	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). <i>Journal of Alzheimer's Disease</i> , 2017, 59, 707-721.	1.2	54
250	Neuropsychological and behavioral changes and weight gain after medial pallidotomy. <i>Annals of Neurology</i> , 1997, 41, 834-835.	2.8	53
251	Letters to the Editor. <i>Movement Disorders</i> , 1998, 13, 851-854.	2.2	53
252	Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 259.	1.7	53

#	ARTICLE	IF	CITATIONS
253	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , 2016, 139, 2050-2062.	3.7	53
254	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 109-110.	1.1	53
255	When and how should treatment be started in Parkinson disease?. <i>Neurology</i> , 2009, 72, S39-43.	1.5	52
256	Deep Brain Stimulator Electrodes Used for Lesioning: Proof of Principle. <i>Neurosurgery</i> , 2001, 49, 363-369.	0.6	51
257	Caffeine consumption and risk of dyskinesia in <scp>CALM</scp>â€œ<scp>PD</scp>. <i>Movement Disorders</i> , 2013, 28, 380-383.	2.2	51
258	Pallidal deep brain stimulation modulates cortical excitability and plasticity. <i>Annals of Neurology</i> , 2018, 83, 352-362.	2.8	51
259	Anticholinergics in Adult-Onset Focal Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1982, 9, 313-319.	0.3	50
260	Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. <i>Journal of Neurosurgery</i> , 2005, 103, 246-251.	0.9	50
261	Benign hereditary chorea revisited: A journey to understanding. <i>Movement Disorders</i> , 2007, 22, 2297-2305.	2.2	50
262	Persistent Hemiballismus with Lesions Outside the Subthalamic Nucleus. <i>Canadian Journal of Neurological Sciences</i> , 1985, 12, 125-128.	0.3	49
263	Perioperative Problems in Parkinson's Disease and Their Management: Apomorphine with Rectal Domperidone. <i>Canadian Journal of Neurological Sciences</i> , 1996, 23, 198-203.	0.3	49
264	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 639-645.	0.7	49
265	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force â€œ An Update. <i>Movement Disorders</i> , 2022, 37, 905-935.	2.2	49
266	A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. <i>Movement Disorders</i> , 2009, 24, 2081-2090.	2.2	48
267	Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. <i>Movement Disorders</i> , 2016, 31, 1243-1247.	2.2	48
268	Unusual tremor syndromes: know in order to recognise. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1191-1203.	0.9	48
269	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3150-3160.	2.4	48
270	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , 2018, 8, S59-S64.	1.5	48

#	ARTICLE	IF	CITATIONS
271	Pallidotomy for Parkinson's Disease. <i>Neurosurgery Clinics of North America</i> , 1998, 9, 325-336.	0.8	47
272	Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 67-75.	0.7	47
273	Long-term double-blind unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1570-1574.	2.2	47
274	Subthalamic nucleus deep brain stimulation for parkinson's disease after successful pallidotomy: Clinical and electrophysiological observations. <i>Movement Disorders</i> , 2004, 19, 1209-1214.	2.2	46
275	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2005, 18, 399-404.	1.8	46
276	The spectrum of orolingual tremor—A proposed classification system. <i>Movement Disorders</i> , 2008, 23, 159-167.	2.2	46
277	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. <i>Lancet Neurology</i> , The, 2012, 11, 643-650.	4.9	46
278	Associated movement disorders in orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 725-729.	0.9	46
279	Levodopa challenge test: indications, protocol, and guide. <i>Journal of Neurology</i> , 2021, 268, 3135-3143.	1.8	46
280	Acquired neurosyphilis presenting as movement disorders. <i>Movement Disorders</i> , 2012, 27, 690-695.	2.2	45
281	Another face of placebo: The lessebo effect in Parkinson disease. <i>Neurology</i> , 2014, 82, 1402-1409.	1.5	45
282	Altered gut microbiome and metabolome in patients with multiple system atrophy. <i>Movement Disorders</i> , 2018, 33, 174-176.	2.2	45
283	<i>Helicobacter pylori</i> Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. <i>Movement Disorders</i> , 2020, 35, 2250-2260.	2.2	45
284	Motor Cortical Stimulation for Parkinsonism in Multiple System Atrophy. <i>Archives of Neurology</i> , 2003, 60, 1554.	4.9	44
285	Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study. <i>Movement Disorders</i> , 2011, 26, 2427-2431.	2.2	44
286	What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 79-84.	0.9	44
287	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	2.2	43
288	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	2.2	43

#	ARTICLE	IF	CITATIONS
289	Electrophysiological features of myoclonusâ€dystonia. <i>Movement Disorders</i> , 2008, 23, 2055-2061.	2.2	42
290	Psychogenic movement disorders: Past developments, current status, and future directions. <i>Movement Disorders</i> , 2011, 26, 1175-1186.	2.2	42
291	Refinement of the DYT15 locus in myoclonus dystonia. <i>Movement Disorders</i> , 2007, 22, 888-892.	2.2	41
292	Imaging changes associated with cognitive abnormalities in Parkinsonâ€™s disease. <i>Brain Structure and Function</i> , 2015, 220, 2249-2261.	1.2	41
293	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinsonâ€™s disease. <i>Brain</i> , 2017, 140, 1371-1383.	3.7	41
294	Treatment of Parkinsonâ€™s disease with agents other than Levodopa and Dopamine Agonists: controversies and new approaches. <i>Canadian Journal of Neurological Sciences</i> , 1984, 11, 210-220.	0.3	40
295	Corticobasal degeneration: Selected developments. <i>Movement Disorders</i> , 2003, 18, 51-56.	2.2	40
296	The curious case of phenocopies in families with genetic Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1793-1802.	2.2	40
297	Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 364-368.	0.9	40
298	<i>Movement</i> Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments. <i>Movement Disorders</i> , 2013, 28, 1980-1986.	2.2	39
299	Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease. <i>Neurology</i> , 2015, 85, 425-432.	1.5	39
300	Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. <i>Journal of Neurosurgery</i> , 1999, 90, 468-477.	0.9	38
301	Pardopruxon in early Parkinson's disease: Results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , 2011, 26, 1464-1476.	2.2	38
302	Withdrawal akathisia: Case reports and a proposed classification of chronic akathisia. <i>Movement Disorders</i> , 2004, 9, 188-192.	2.2	37
303	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: Differential effects on bradykinesia. <i>Movement Disorders</i> , 2007, 22, 328-333.	2.2	37
304	What is â€œessentialâ€ about essential tremor? A diagnostic placeholder. <i>Movement Disorders</i> , 2018, 33, 58-61.	2.2	37
305	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	2.2	37
306	Gestes antagonistes in psychogenic dystonia. <i>Movement Disorders</i> , 2004, 19, 331-332.	2.2	36

#	ARTICLE	IF	CITATIONS
307	Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. <i>Neurogenetics</i> , 2005, 6, 151-158.	0.7	36
308	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. <i>Neurobiology of Aging</i> , 2015, 36, 545.e9-545.e14.	1.5	36
309	Contribution of insula in Parkinson's disease: A quantitative meta-analysis study. <i>Human Brain Mapping</i> , 2016, 37, 1375-1392.	1.9	36
310	[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , 2018, 223, 589-595.	1.2	36
311	High Dose Anticholinergic Therapy in Adult Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1986, 13, 42-46.	0.3	35
312	Deep Brain Stimulator Electrodes Used for Lesioning: Proof of Principle. <i>Neurosurgery</i> , 2001, 49, 363-369.	0.6	35
313	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology</i> , The, 2006, 5, 200-202.	4.9	35
314	Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 80-86.	1.1	35
315	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , 2018, 90, e2059-e2067.	1.5	35
316	Subdural motor cortex stimulation in Parkinson's disease does not modify movement-related rCBF pattern. <i>Movement Disorders</i> , 2007, 22, 2113-2116.	2.2	33
317	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 41-48.	1.1	33
318	Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies. <i>Neuroscience Letters</i> , 2018, 665, 18-21.	1.0	33
319	Natural History of Oppenheim's Dystonia (DYT1) in Israel. <i>Journal of Child Neurology</i> , 2003, 18, 325-330.	0.7	32
320	Double-blind study of pramipexole, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 738-746.	2.2	32
321	Movement disorders in patients with diabetes mellitus. <i>Journal of the Neurological Sciences</i> , 2012, 314, 5-11.	0.3	32
322	Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links SCN1A to early onset parkinsonian features. <i>Epilepsia</i> , 2017, 58, e44-e48.	2.6	32
323	Letters to the editor. <i>Movement Disorders</i> , 1995, 10, 527-529.	2.2	31
324	Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. <i>Neuroscience Letters</i> , 2004, 372, 226-229.	1.0	31

#	ARTICLE	IF	CITATIONS
325	Homozygous and heterozygous PINK1 mutations: Considerations for diagnosis and care of Parkinson's disease patients. <i>Movement Disorders</i> , 2006, 21, 875-879.	2.2	31
326	Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. <i>Movement Disorders</i> , 2017, 32, 193-202.	2.2	31
327	ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 512-520.	0.8	31
328	Alphamethylparatyrosine and Tetrabenazine in Movement Disorders. <i>Clinical Neuropharmacology</i> , 1982, 5, 375-388.	0.2	30
329	Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: The spectrum of hemiparkinsonism-hemiatrophy syndrome. <i>Movement Disorders</i> , 1995, 10, 489-495.	2.2	30
330	The perioperative management of Parkinson's disease revisited. <i>Neurologic Clinics</i> , 2004, 22, 367-377.	0.8	30
331	Antidepressants in the Treatment of Psychosis With Comorbid Depression in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 90-92.	0.2	30
332	Development of a Non-Motor Fluctuation Assessment Instrument for Parkinson Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-13.	0.6	30
333	Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes. <i>Human Brain Mapping</i> , 2017, 38, 283-292.	1.9	30
334	Genomewide Association Studies of <i>LRRK2</i> Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 76-88.	2.8	30
335	Neurodegenerative disease and the evolution of art: The effects of presumed corticobasal degeneration in a professional artist. <i>Movement Disorders</i> , 2003, 18, 294-302.	2.2	29
336	Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 893-903.	2.2	29
337	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer's Disease, Parkinson's Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , 2019, 13, 1259.	1.4	29
338	The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes. <i>Movement Disorders</i> , 2021, 36, 594-598.	2.2	28
339	Microelectrode Recordings Define the Ventral Posteromedial Pallidotomy Target. <i>Stereotactic and Functional Neurosurgery</i> , 1998, 71, 153-163.	0.8	27
340	Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. <i>Movement Disorders</i> , 2005, 20, 371-377.	2.2	27
341	The Value of GRE, ADC and Routine MRI in Distinguishing Parkinsonian Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 389-402.	0.3	27
342	Integrated Therapy for Functional Movement Disorders: Time for a Change. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 169-174.	0.8	27

#	ARTICLE	IF	CITATIONS
343	'Don't delay, start today': delaying levodopa does not delay motor complications. <i>Brain</i> , 2014, 137, 2628-2630.	3.7	26
344	Repurposing drugs to treat L-DOPA-induced dyskinesia in Parkinson's disease. <i>Neuropharmacology</i> , 2019, 147, 11-27.	2.0	26
345	Neuronal intranuclear inclusion disease: Two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1274-1279.	2.2	25
346	Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 222-225.	1.1	25
347	Unfreezing of gait in patients with Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 675-677.	4.9	25
348	Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease. <i>Movement Disorders</i> , 2018, 33, 1700-1711.	2.2	25
349	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2146-2159.	0.7	25
350	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.	1.4	25
351	Clinical Findings in a Large Family With a Parkin Ex3 ⁺ 40 Mutation. <i>Archives of Neurology</i> , 2004, 61, 701.	4.9	24
352	Reduced Intracortical and Interhemispheric Inhibitions in Corticobasal Syndrome. <i>Journal of Clinical Neurophysiology</i> , 2008, 25, 304-312.	0.9	24
353	Dystonia in complex regional pain syndrome type I. <i>Annals of Neurology</i> , 2010, 67, 412-414.	2.8	24
354	Pedunculopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 613-616.	0.9	24
355	Alternating Hemiplegia of Childhood as a New Presentation of Adenylate Cyclase 5-Mutation-Associated Disease: A Report of Two Cases. <i>Journal of Pediatrics</i> , 2017, 181, 306-308.e1.	0.9	24
356	Corticobasal degeneration. <i>International Review of Neurobiology</i> , 2019, 149, 87-136.	0.9	24
357	Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 961-962.	0.9	24
358	Telemedicine in Movement Disorders: Leçons du COVID-19. <i>Movement Disorders</i> , 2020, 35, 1893-1896.	2.2	24
359	Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0153852.	1.1	24
360	Pallidotomy for Tremor. <i>Movement Disorders</i> , 1998, 13, 107-110.	2.2	23

#	ARTICLE	IF	CITATIONS
361	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopaâ€”carbidopa intestinal gel infusion. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 968-971.	1.1	23
362	The Interaction Between Neuroinflammation and Î²-Amyloid in Cognitive Decline in Parkinsonâ€™s Disease. <i>Molecular Neurobiology</i> , 2020, 57, 492-501.	1.9	23
363	Myoclonus in complex regional pain syndrome. <i>Movement Disorders</i> , 2009, 24, 314-316.	2.2	22
364	Longâ€”term effect of unilateral pallidotomy on levodopaâ€”induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1496-1498.	2.2	22
365	Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 116-124.	0.8	22
366	Antidepressants and psychosis in Parkinson disease: a case series. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 601-604.	1.3	21
367	Diagnostic delay in Parkinson's disease caused by PRKN mutations. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 217-220.	1.1	21
368	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 412-423.	0.9	21
369	Neuroprotection in Parkinson's disease: and now for something completely different?. <i>Lancet Neurology</i> , The, 2006, 5, 990-991.	4.9	20
370	The G2019S <i>LRRK2</i> mutation in Brazilian patients with Parkinson's disease: Phenotype in monozygotic twins. <i>Movement Disorders</i> , 2008, 23, 290-294.	2.2	20
371	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBSâ€”PD). <i>Movement Disorders</i> , 2010, 25, 1530-1537.	2.2	20
372	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2011, 26, 608-613.	2.2	20
373	Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. <i>Journal of Neurosurgery</i> , 2011, 114, 1428-1431.	0.9	20
374	Implications of nocturnal symptoms towards the early diagnosis of Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2014, 121, 49-57.	1.4	19
375	Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy. <i>Movement Disorders</i> , 2017, 32, 1465-1473.	2.2	19
376	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 1123.	1.1	19
377	Case 1, 1994: Rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. <i>Movement Disorders</i> , 1994, 9, 358-366.	2.2	18
378	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. <i>Movement Disorders</i> , 2011, 26, 1348-1352.	2.2	18

#	ARTICLE	IF	CITATIONS
379	Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 610-614.	2.2	18
380	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 503-510.	1.5	18
381	Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 105-118.	1.0	18
382	Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020, 35, 2090-2095.	2.2	18
383	Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. , 2017, 8, 261.		18
384	Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. <i>Movement Disorders</i> , 2003, 18, 942-948.	2.2	17
385	Orthostatic tremor in progressive supranuclear palsy. <i>Movement Disorders</i> , 2007, 22, 1192-1194.	2.2	17
386	Initiating dopaminergic treatment in Parkinson's disease. <i>Lancet, The</i> , 2014, 384, 1164-1166.	6.3	17
387	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 915-918.	1.1	17
388	Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [¹¹ C]raclopride positron emission tomography imaging study. <i>Human Brain Mapping</i> , 2015, 36, 2592-2601.	1.9	17
389	<p>Orthostatic hypotension and dementia incidence: links and implications</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2181-2194.	1.0	17
390	Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?. <i>Movement Disorders</i> , 2021, 36, 1483-1484.	2.2	17
391	Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0173944.	1.1	17
392	Deep Bayesian networks for uncertainty estimation and adversarial resistance of white matter hyperintensity segmentation. <i>Human Brain Mapping</i> , 2022, 43, 2089-2108.	1.9	17
393	Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. <i>Movement Disorders</i> , 1996, 11, 448-449.	2.2	16
394	Diagnosing psychogenic movement disorders— which criteria should be used in clinical practice?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 134-135.	2.7	16
395	Clinical heterogeneity in Progressive Supranuclear Palsy: Challenges to diagnosis, pathogenesis and future therapies. <i>Movement Disorders</i> , 2014, 29, 1707-1709.	2.2	16
396	Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 38, 217.e7-217.e8.	1.5	16

#	ARTICLE	IF	CITATIONS
397	Expanding the phenomenology of benign hereditary chorea: Evolution from chorea to myoclonus and dystonia. <i>Movement Disorders</i> , 2011, 26, 2296-2297.	2.2	15
398	Designing Clinical Trials for Dystonia. <i>Neurotherapeutics</i> , 2014, 11, 117-127.	2.1	15
399	Paroxysmal Asymmetric Dystonic Arm Posturing—A Less Recognized but Characteristic Manifestation of ATP1A3-related disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 312-315.	0.8	15
400	Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 25-27.	1.1	15
401	A case of neurosyphilis presenting with myoclonus, cerebellar ataxia, and speech disturbance. <i>Movement Disorders</i> , 2012, 27, 794-794.	2.2	14
402	Clinicopathological review of pallidonigroluysian atrophy. <i>Movement Disorders</i> , 2013, 28, 274-281.	2.2	14
403	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 67-69.	0.8	14
404	Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway. <i>Neurobiology of Disease</i> , 2019, 124, 176-182.	2.1	14
405	The evidence for multidisciplinary care in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 539-549.	1.4	14
406	Improved Segmentation of the Intracranial and Ventricular Volumes in Populations with Cerebrovascular Lesions and Atrophy Using 3D CNNs. <i>Neuroinformatics</i> , 2021, 19, 597-618.	1.5	14
407	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021, 6, 80.	1.7	14
408	GDNF in Parkinson's disease: The perils of post-hoc power. <i>Journal of Neuroscience Methods</i> , 2007, 163, 193-196.	1.3	13
409	Functional/psychogenic movement disorders: Do we know what they are?. <i>Movement Disorders</i> , 2014, 29, 1696-1697.	2.2	13
410	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 361-367.	0.9	13
411	Action Myoclonus and Seizure in Kufor-Rakeb Syndrome. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 195-199.	0.8	13
412	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018, 33, 960-965.	2.2	12
413	Sleep-related motor and behavioral disorders: Recent advances and new entities. <i>Movement Disorders</i> , 2018, 33, 1042-1055.	2.2	12
414	Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. <i>Movement Disorders</i> , 2006, 21, 2251-2254.	2.2	11

#	ARTICLE	IF	CITATIONS
415	Reversible dopamine agonist induced anterocollis in a multiple system atrophy patient. <i>Movement Disorders</i> , 2007, 22, 2292-2293.	2.2	11
416	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. <i>Movement Disorders</i> , 2009, 24, 2370-2378.	2.2	11
417	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 43, 151-156.	2.5	11
418	Dancing Dorsal Quadrilaterals. <i>JAMA Neurology</i> , 2019, 76, 351.	4.5	11
419	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 121-126.	1.1	11
420	Parkinson's Disease and COVID-19: Do We Need to Be More Patient?. <i>Movement Disorders</i> , 2021, 36, 277-277.	2.2	11
421	Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. <i>Movement Disorders</i> , 2022, 37, 1304-1309.	2.2	11
422	Neuronal activity in the globus pallidus of multiple system atrophy patients. <i>Movement Disorders</i> , 2004, 19, 1485-1492.	2.2	10
423	Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. <i>Journal of Human Genetics</i> , 2011, 56, 671-675.	1.1	10
424	Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 348-350.	2.4	10
425	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 184-187.	0.8	10
426	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinson's Disease</i> , 2018, 8, 131-139.	1.5	10
427	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Clinical Autonomic Research</i> , 2019, 29, 603-614.	1.4	10
428	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 127-132.	1.1	10
429	Diagnosing functional neurological disorder: seeing the whole picture. <i>CNS Spectrums</i> , 2021, 26, 593-600.	0.7	10
430	Sporadic case of dentatorubral pallidoluysian atrophy with no CAG repeat expansion and no intranuclear inclusions. <i>Movement Disorders</i> , 2004, 19, 580-583.	2.2	9
431	Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy. <i>Experimental Brain Research</i> , 2010, 206, 1-13.	0.7	9
432	The grasp reflex: A symptom in need of treatment. <i>Movement Disorders</i> , 2010, 25, 2479-2485.	2.2	9

#	ARTICLE	IF	CITATIONS
433	LRRK2 and Parkin mutations in a family with parkinsonism—Lack of genotype—phenotype correlation. <i>Neurobiology of Aging</i> , 2010, 31, 721-722.	1.5	9
434	Genome-wide variant by serum urate interaction in Parkinson's disease. <i>Annals of Neurology</i> , 2015, 78, 731-741.	2.8	9
435	DYT-TUBB4A (DYT4 Dystonia). <i>Neurology</i> , 2021, 96, e1887-e1897.	1.5	9
436	Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. <i>BMC Neurology</i> , 2021, 21, 459.	0.8	9
437	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. <i>Movement Disorders</i> , 2022, 37, 1265-1271.	2.2	9
438	Insights into brain function through the examination of art: the influence of neurodegenerative diseases. <i>NeuroReport</i> , 2004, 15, 933-937.	0.6	8
439	Successful treatment of functional palatal tremor: Insights into pathogenesis and management. <i>Movement Disorders</i> , 2015, 30, 875-876.	2.2	8
440	Paroxysmal Hemiballism/Hemichorea Resulting from Transient Ischemic Attacks. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 303-305.	0.8	8
441	Oculogyric crises in PLA2G6 associated neurodegeneration. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 111-112.	1.1	8
442	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 200-203.	1.1	8
443	The retina as a window to the basal ganglia: Systematic review of the potential link between retinopathy and hyperkinetic disorders in diabetes. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 194-198.	1.1	8
444	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021, 105, 378.e1-378.e9.	1.5	8
445	Protracted course progressive supranuclear palsy. <i>European Journal of Neurology</i> , 2022, 29, 2220-2231.	1.7	8
446	Manipulating the dopaminergic system in Parkinson's disease. , 1987, 32, 51-76.		7
447	—Weight-holding tremor—: An unusual task-specific form of essential tremor?. <i>Movement Disorders</i> , 1995, 10, 228-229.	2.2	7
448	Letters to the editor. <i>Movement Disorders</i> , 1995, 10, 235-237.	2.2	7
449	FIXED DYSTONIA UNRESPONSIVE TO PALLIDAL STIMULATION IMPROVED BY MOTOR CORTEX STIMULATION. <i>Neurology</i> , 2007, 69, 1062-1063.	1.5	7
450	Early-onset tardive dyskinesia in a neuroleptic-naïve patient exposed to low-dose quetiapine. <i>Movement Disorders</i> , 2011, 26, 2297-2298.	2.2	7

#	ARTICLE	IF	CITATIONS
451	Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 66-74.	0.8	7
452	The clinical significance of lower limb tremors. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 165-171.	1.1	7
453	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. <i>Frontiers in Neurology</i> , 2020, 11, 574.	1.1	7
454	Primary brain calcification due to a homozygous MYORG mutation causing isolated paroxysmal kinesigenic dyskinesia. <i>Brain</i> , 2020, 143, e36-e36.	3.7	7
455	Movement Disorders Associated with Hypogonadism. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 997-1011.	0.8	7
456	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7292.	1.8	7
457	Myoclonus in parkinsonian disorders. <i>Advances in Neurology</i> , 2002, 89, 77-83.	0.8	7
458	Motor and non-motor fluctuations. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 157-184.	1.0	6
459	Tremor in Spinocerebellar Ataxia Type 12. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 76-78.	0.8	6
460	Dystonic Pseudo Foot Drop. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 295-298.	0.8	6
461	Placebos in clinical trials: unravelling a complex phenomenon. <i>Lancet Neurology</i> , The, 2017, 16, 28-29.	4.9	6
462	Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. <i>Cmaj</i> , 2018, 190, E50-E52.	0.9	6
463	Successful pallidotomy for post-hyperglycemic hemichorea-ballism. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 228-230.	1.1	6
464	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 44-45.	1.1	6
465	<i>Movement Disorders: Diagnosis and Assessment.</i> , 2008, , 293-325.		6
466	Tremor-Dominant Pantothenate Kinase-associated Neurodegeneration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 772-774.	0.8	5
467	Tracking the course of prodromal Parkinson's disease. <i>Brain</i> , 2017, 140, 259-262.	3.7	5
468	A Distinct EEG Marker of Celiac Disease-Related Cortical Myoclonus. <i>Movement Disorders</i> , 2021, 36, 999-1005.	2.2	5

#	ARTICLE	IF	CITATIONS
469	Axial Impairment Following Deep Brain Stimulation in Parkinson's Disease: A Surgicogenomic Approach. <i>Journal of Parkinson's Disease</i> , 2022, 12, 117-128.	1.5	5
470	<sc>DYT4</sc> (<sc>DYT4</sc> Dystonia): Clinical Anthology of 11 Cases and Systematized Review. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 659-675.	0.8	5
471	Essential palatal tremor. <i>Movement Disorders</i> , 2001, 16, 1202-1203.	2.2	4
472	Rapidly progressive behavioral changes and parkinsonism in a 68-year-old man. <i>Movement Disorders</i> , 2004, 19, 534-543.	2.2	4
473	Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 277-286.	0.3	4
474	Stem cell therapy for Parkinson's disease. <i>Annals of Neurology</i> , 2012, 71, 283-283.	2.8	4
475	Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. <i>Biomarkers in Medicine</i> , 2015, 9, 89-97.	0.6	4
476	Comment on "Is it Useful to Classify PSP and CBD as Different Disorders?". <i>Movement Disorders Clinical Practice</i> , 2018, 5, 564-565.	0.8	4
477	Isolated Abdominal Motor Seizures of Mesial Parietal Origin: Epileptic Belly Dancing?. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 396-399.	0.8	4
478	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1561-1569.	1.5	4
479	<sc>Age-Related</sc> Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , 2020, 35, 1239-1245.	2.2	4
480	Preferences for Communication About End-of-Life Care in Atypical Parkinsonism. <i>Movement Disorders</i> , 2021, 36, 2116-2125.	2.2	4
481	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 1964-1967.	2.2	4
482	Spinocerebellar Ataxia 40: Another Etiology Underlying Essential Tremor Syndrome. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 944-946.	0.8	4
483	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. <i>GeroScience</i> , 2022, 44, 1575-1598.	2.1	4
484	Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 252-252.	2.2	3
485	Hemiballism "Hemichorea". , 2013, , 151-161.		3
486	Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 447-448.	0.3	3

#	ARTICLE	IF	CITATIONS
487	Will New Genetic Techniques Like Exome Sequencing Obviate the Need for Clinical Expertise? No. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 39-41.	0.8	3
488	Infantile-onset hand dystonia with intellectual disability. <i>Neurology</i> , 2018, 90, 333-335.	1.5	3
489	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. <i>Movement Disorders</i> , 2018, 33, 1195-1203.	2.2	3
490	Interhemispheric pathways in agenesis of the corpus callosum and Parkinson's disease. <i>Brain Stimulation</i> , 2020, 13, 360-362.	0.7	3
491	Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1047-1055.	1.5	3
492	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 171-177.	2.2	3
493	Bilingualism in Parkinson's disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 199-212.	0.8	3
494	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 816465.	1.3	3
495	Targeted copy number variant identification across the neurodegenerative disease spectrum. <i>Molecular Genetics & Genomic Medicine</i> , 0, , .	0.6	3
496	Structural and functional magnetic resonance imaging in neurodegenerative diseases. , 2005, , 253-289.		2
497	Multiple system atrophy. , 2005, , 623-662.		2
498	In pursuit of prodromal Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 27-28.	4.9	2
499	Is there even such a thing as "idiopathic normal pressure hydrocephalus"? <i>Annals of Neurology</i> , 2017, 82, 1032-1032.	2.8	2
500	Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 782-784.	0.3	2
501	Jumping to overcome freezing of gait while turning in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 349-351.	1.1	2
502	Initiating pharmacotherapy in early Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 643-644.	4.9	2
503	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 80.	1.1	2
504	Is clinical assessment enough? Moving towards early differentiation of neurodegenerative parkinsonisms. <i>Brain</i> , 2021, 144, 1040-1042.	3.7	2

#	ARTICLE	IF	CITATIONS
505	Reply to: "The Logic and Pitfalls of Parkinson's as Brain-First Subtypes," Movement Disorders, 2021, 36, 786-787.	2.2	2
506	Dream Enactment Behavior Disorder Associated with Pallido-Nigro-Luysian Degeneration and Tau Proteinopathy. Movement Disorders Clinical Practice, 2021, 8, 594-599.	0.8	2
507	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. Clinical Autonomic Research, 2021, 31, 729-736.	1.4	2
508	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 1: Genetic Disorders. Movement Disorders Clinical Practice, 2022, 9, 297-310.	0.8	2
509	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders. Movement Disorders Clinical Practice, 2022, 9, 311-325.	0.8	2
510	Case of a Man with Hemichorea and Behavioral Changes: "A Red Herring." Movement Disorders Clinical Practice, 2022, 9, 501-507.	0.8	2
511	69-Year-old man with gait disturbance and parkinsonism. Movement Disorders, 2001, 16, 548-561.	2.2	1
512	Selected genetically engineered models relevant to human neurodegenerative disease. , 2005, , 176-195.		1
513	Therapy of the Motor Features of Parkinson's Disease. Blue Books of Neurology, 2010, 34, 252-272.	0.1	1
514	Crossing the borders between neurology and psychiatry in functional neurological disorders. Movement Disorders, 2011, 26, 1373-1374.	2.2	1
515	Commentary. Movement Disorders, 2013, 28, 1806-1807.	2.2	1
516	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 53-58.	0.8	1
517	Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders. Clinical Neurophysiology Practice, 2021, 6, 103-108.	0.6	1
518	Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. Canadian Journal of Neurological Sciences, 2021, , 1-5.	0.3	1
519	Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease. Movement Disorders, 2021, 36, 1125-1125.	2.2	1
520	Teaching Video NeuroImage: "Weighing in on an Unusual Tremor. Neurology, 2021, 97, e970-e971.	1.5	1
521	Irreversible extreme freezing of gait after dopamine agonist withdrawal. Clinical Case Reports (discontinued), 2021, 9, e04712.	0.2	1
522	The Discovery of α -Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. Movement Disorders Clinical Practice, 2021, 8, 1189-1193.	0.8	1

#	ARTICLE	IF	CITATIONS
523	Oculogyric Crisis Phenotype of Levodopa-Induced Ocular Dyskinesia. <i>Movement Disorders Clinical Practice</i> , 0, , .	0.8	1
524	Pallidal neuronal activity in multiple system atrophy type P and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 15-17.	1.1	1
525	Corticobasal degeneration. , 2005, , 682-696.		0
526	Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus. , 2005, , 227-250.		0
527	Approach to the patient presenting with parkinsonism. , 2005, , 551-560.		0
528	Current and potential treatments of Parkinson's disease. , 2005, , 612-622.		0
529	Reply: The variability of levodopa response in Parkinson's disease: Is sensitization reversible?. <i>Movement Disorders</i> , 2008, 23, 925-925.	2.2	0
530	Reply to Drs. Kurlan, Fasano, and Evans: A clinically useful definition of stereotypies. <i>Movement Disorders</i> , 2013, 28, 405-406.	2.2	0
531	Reply to letter: multiple system atrophy-parkinsonism with slow progression and prolonged survival: A diagnostic catch. <i>Movement Disorders</i> , 2013, 28, 408-408.	2.2	0
532	Lessons learned: neuroprotective trials in Parkinson's disease. , 0, , 265-279.		0
533	The Clinical Spectrum of Functional/Psychogenic Dystonia. , 0, , 217-223.		0
534	Dancing Dorsal Quadrilateralsâ€”Organic or Functional?â€”Reply. <i>JAMA Neurology</i> , 2019, 76, 985.	4.5	0
535	Reply to â€œStudying reproducibility of data-driven Parkinson's disease subtypesâ€• <i>Parkinsonism and Related Disorders</i> , 2019, 66, 245-246.	1.1	0
536	Heart rate variability biomarkers of leucine-rich repeat kinase 2-associated Parkinson's disease. , 2020, , .		0
537	Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia. <i>Movement Disorders</i> , 2021, 36, 265-266.	2.2	0
538	Hyperglycemic hemichorea presenting with normal MRI and striatal hyperdensity on CT. <i>Neurological Sciences</i> , 2021, 42, 4341-4343.	0.9	0
539	Sleepiness and Sleep Attacks in Parkinsonâ€™s Disease. <i>Advances in Behavioral Biology</i> , 2002, , 385-390.	0.2	0
540	Psychogenic Dystonia. <i>Medical Psychiatry</i> , 2006, , 277-288.	0.2	0

#	ARTICLE	IF	CITATIONS
541	Psychogenic dystonia. , 2012, , 307-319.		0
542	Isolated Ear Clicks with Partial Voluntary Control. Tremor and Other Hyperkinetic Movements, 2020, 10, 55.	1.1	0